TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03389763

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: a rate of infusion will be increased by 50% every 5 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: a rate of infusion will be increased by 50% every 5 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: a rate of infusion will be increased by 50% every 5 minutes
Study: NCT00099580

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC2592
Description: continuous subcutaneous infusion (via pump), dose based on subject body weight

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: continuous subcutaneous infusion (via pump), dose based on subject body weight
Study: NCT00950716

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Patient Peer Support and Empowerment
Description: 30 mentors are themselves diabetes patients who have good self care and are motivated to support their peers. The mentors will be trained to deliver peer support intervention under supervision by a program manager. The 300 diabetes patients (mentees) randomized to the peer support group are the intervention targets of these 30 mentors. Telephone-Linked-Communication (TLC) system will be a tool of the mentors for education to the mentees. TLC system utilizes an automatic, interactive, computer-controlled telephone system to monitor and promote diabetes self-management.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Subjects in Usual CAre will receive standard care with clinicians' usual follow-up and referral with education to diabetes nurses if deemed necessary at in-charge clinicians' discretion.
Study: NCT04356807

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Reflex Locomotion Therapy
Description: The exercises corresponding to the motor complexes of the 1st phase of the rolling reflex and the original creeping reflex were performed, dedicating one minute to each side and performing two repetitions in each session.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Passive Joint Mobilizations
Description: Passive Joint Mobilizations with articular pressure described by Moyer-Mileur, et al. 1995 and modified by Vignochi, et al. 2008

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Massage
Description: Soft massage with soft pressures in limbs, tactile stimulation and no motion.
Study: NCT01117987

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib
Description: Participants, who received imatinib 200 mg in the core study, CQTI571A2301 (NCT00902174), and completed the core study, received imatinib 200 mg every day (qd) in the extension. Participants, who were randomized to receive imatinib 400 mg in the core study and completed the core study, received imatinib 400 mg qd in the extension. Participants, who terminated early from the core study or who were randomized to placebo and completed the core study, started the extension with imatinib 200 mg qd. After 2 weeks, the dose was increased to 400 mg qd if tolerated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib
Description: Participants, who received imatinib 200 mg in the core study, CQTI571A2301 (NCT00902174), and completed the core study, received imatinib 200 mg every day (qd) in the extension. Participants, who were randomized to receive imatinib 400 mg in the core study and completed the core study, received imatinib 400 mg qd in the extension. Participants, who terminated early from the core study or who were randomized to placebo and completed the core study, started the extension with imatinib 200 mg qd. After 2 weeks, the dose was increased to 400 mg qd if tolerated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: To preserve the blind of the core study until the core study, CQTI571A2301 (NCT00902174), was completed, participants received a blinded study drug package containing a 70-tablet bottle of imatinib and a 70-tablet bottle of matching placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: To preserve the blind of the core study until the core study, CQTI571A2301 (NCT00902174), was completed, participants received a blinded study drug package containing a 70-tablet bottle of imatinib and a 70-tablet bottle of matching placebo.
Study: NCT02721368

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuramis® Volume Lidocaine
Description: hyaluronic acid filler

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Juvederm® Voluma® with Lidocaine
Description: hyaluronic acid filler
Study: NCT03316040

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: JIC
Description: The Join In Circuit on HIV, love and sexuality is a mobile learning system on the core topics of reproductive health and HIV and AIDS, targeting young people. JIC works with person-to-person communication in order to give an opportunity for discussion and for providing information in an open, engaging atmosphere. The JIC uses interactive exercises, pictorial aids and edutainment strategies to promote behavior change among young people aged 15 years and older.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: JIC
Description: The Join In Circuit on HIV, love and sexuality is a mobile learning system on the core topics of reproductive health and HIV and AIDS, targeting young people. JIC works with person-to-person communication in order to give an opportunity for discussion and for providing information in an open, engaging atmosphere. The JIC uses interactive exercises, pictorial aids and edutainment strategies to promote behavior change among young people aged 15 years and older.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: JIC
Description: The Join In Circuit on HIV, love and sexuality is a mobile learning system on the core topics of reproductive health and HIV and AIDS, targeting young people. JIC works with person-to-person communication in order to give an opportunity for discussion and for providing information in an open, engaging atmosphere. The JIC uses interactive exercises, pictorial aids and edutainment strategies to promote behavior change among young people aged 15 years and older.
Study: NCT02248116

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talsaclidine
Study: NCT01041209

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strategy based on BPS guided antibiotic use
Description: In this study a strategy based on BPS guided antibiotic use in children with community acquired pneumonia implementation will be compared with enforced guideline.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enforced Guidelines
Description: In this study a strategy based on BPS guided antibiotic use in children with community acquired pneumonia implementation will be compared with enforced guideline.
Study: NCT04319458

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fotonovela
Description: Secret Feelings/Sentimientos Secretos

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: NIH Brochure: Depression: What You Need to Know
Study: NCT00756717

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0752
Description: Women who are post menopausal will receive letrozole 2.5 mg by mouth one time per day for 24 days. Women who are pre menopausal, or who have a contraindication to letrozole will receive tamoxifen 20 mg orally one time per day for a period of 24 days. Starting on day 15 of this 24 day period all patients will receive the oral gamma-secretase inhibitor drug MK-0752 at a dose of 350 mg for three days on, then off four days, then three days on, for a total of 6 doses over a period of 10 days.
Study: NCT03211455

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: intravenous lidocaine versus placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: isotonic saline
Description: intravenous isotonic saline
Study: NCT02074956

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sterile buffer containing 10 mmol Tris and 169 mmol of NaCl in 0.8 mL of aqueous solution. This is the identical buffer solution in which H4 and IC31 are formulated.
Study: NCT01304186

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored Information
Description: The intervention comprises a computer-based application designed to provide individually-tailored information to participants in an interactive fashion.
Study: NCT01503463

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Home telemonitoring of patients with CHF
Description: Patients in the intervention group receive a personal 1-lead or 12-lead ECG recorder, a blood pressure monitor, a digital weight scale and appropriate education regarding the use of these devices. ThA trained nurse visits the patients weekly during the first month, and monthly thereafter, to confirm the appropriate use of the devices and services, to monitor symptoms, adherence to pharmacological and non-pharmacological treatment, and to complete the case record forms when necessary.~If there is deterioration in the monitored vital signs, or if symptoms are reported, the allocated cardiologist is informed via the telehealth platform and has to decide whether the patient has to visit the hospital as in- or outpatient and whether the therapy has to be modified.
Study: NCT01735786

Intervention type: DEVICE
Intervention: EndoClot
Description: EndoClot hemostat is applied immediately after EMR to achieve hemostasis.
Study: NCT03538925

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AAC Generative Language Intervention
Description: Parent/Caregiver AAC App Operational Training + Direct AAC Input-Output Language Intervention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care / Business as Usual
Description: Parent/Caregiver AAC App Operational Training

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard of Care / Business as Usual
Description: Parent/Caregiver AAC App Operational Training
Study: NCT01909739

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atrovastatin
Description: Atrovastatin 80mg was administered orally on the evening before surgery. Before anesthesia induction, atrovastatin 40mg was administered orally. And atrovastatin 40mg were administered orally in the evening of postoperative days 0, 1, and 2.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 80mg was administered orally on the evening before surgery. Before anesthesia induction, placebo 40mg was administered orally. And placebo 40mg were administered orally in the evening of postoperative days 0, 1, and 2.
Study: NCT00679250

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levocetirizine
Description: 5 mg once nightly before visit

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo to levocetirizine
Description: 1 tablet once nightly before visit
Study: NCT02900482

Intervention type: OTHER
Intervention: Sampling saliva

Intervention type: OTHER
Intervention: Sampling saliva

Intervention type: OTHER
Intervention: Sampling saliva
Study: NCT04335838

Intervention type: OTHER
Intervention: retrospective analysis
Description: The investigators retrospectively analyzed the outcome and possible prognostic factors in polytrauma patients.
Study: NCT01649791

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative study
Study: NCT00570167

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hip resurfacacing
Description: Hip resurfacing with cementless acetabular cup and cemented femoral head

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cementless total hip arthroplasty with m-o-m bearings
Description: Cementless monoblock acetabular cup and cementless femoral stem with modular large head and metal-on-metal bearings..
Study: NCT01649791

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lymph node biopsy
Description: Correlative study

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bone marrow aspiration
Description: Correlative study

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative study

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: flow cytometry
Description: Correlative study
Study: NCT04257279

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ExcelsiusGPS™
Description: The ExcelsiusGPS™ is a Robotic Positioning System that includes a computer controlled robotic arm, hardware, and software that enables real time surgical navigation and robotic guidance using radiological patient images (pre-operative CT, intra-operative CT and fluoroscopy), using a dynamic reference base and positioning camera.
Study: NCT03843827

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laryngeal Mask Airway
Description: The aim of this study is to compare between cLMA and I gel regarding insertion success rate, the time of insertion, leaking pressure, assessment of position by fiber optic, hemodynamic, Spo2 for each device during insertion and maintenance of general anaesthesia and postoperative complications in obese patients

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: I gel Airway
Description: I gel is a new type of laryngeal mask and doesn't have an inflatable cuff. Because of its thermoplastic elastomer structure, it exactly adapts to the supraglottic tissue by binding with body temperature, thus minimising air leakage
Study: NCT01066403

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pergolide
Description: 0,3 mg pergolide (the first two days begin with 0,05mg, then increase of dose of 0,1mg every 3 days for a maximum of 0,3mg/d, taken orally 3x 0,1mg/day). Then stable dose of 0,3mg for one week.. Subsequently slow (for 8 days) reduction of dosage of 0,1mg every 3 days for 6 days then 0,05mg every day for the last two days.~Placebo group is identical in appearance and number of placebo capsules, in the same starting and maintenance scheme as for the pergolide group.
Study: NCT04363515

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social support network counseling intervention
Description: Pilot social support counseling intervention for kidney transplant candidates along with their social support networks
Study: NCT02276326

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: VSL#3 sachets
Description: 4 sachets a day for 4 months
Study: NCT03459482

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food Elimination Diet
Description: Subjects asked to participate in a food elimination diet, either True or Sham to evaluate the effects on their IBS symptoms

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Food Elimination Diet
Description: Subjects asked to participate in a food elimination diet, either True or Sham to evaluate the effects on their IBS symptoms
Study: NCT03801083

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tumor Infiltrating Lymphocytes (TIL)
Description: TIL are to be infused intravenously through a central vein catheter over 20-30 minutes followed by Aldesleukin, administered at a dose of 600,000 IU/kg (based on total body weight) as an intravenous bolus over a 15-minute period approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to a maximum of 6 doses.
Study: NCT03871998

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Skin barrier protection in the first 2 months of life
Description: Skin barrier protection in the first 2 months of life using a commercially available moisturiser from birth 2 months. Twice daily, whole-body application.
Study: NCT01719289

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PROGRAVIDA
Description: Women in the intervention group receive a program based on psycho-education and problem solving techniques, delivered by a nurse assistant at the women's homes. The program comprises 8 sessions, 6 during pregnancy and 2 after delivery. Intensity of depressive symptoms is assessed using the PHQ-9, at the beginning of the sessions. Women with severe depression are referred to the family doctor and are assessed for the need of antidepressant medication.
Study: NCT00303303

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Crotaline Polyvalent Immune Fab (ovine) (active initial and maintenance therapy)
Description: Crotaline Polyvalent Immune Fab (Ovine), 4 vials initially; Second 4-vial dose two hours later if needed to achieve initial control of the envenomation syndrome; active maintenance therapy with 2 vials administered 6, 12, and 18 hours after initial control is achieved.
Study: NCT01839838

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton Therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton Therapy
Study: NCT00303303

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Crotaline Immune Fab (ovine) (active initial therapy; placebo maintenance therapy)
Description: Crotaline Polyvalent Immune Fab (Ovine), 4 vials initially; Second 4-vial dose two hours later if needed to achieve initial control of the envenomation syndrome; placebo maintenance therapy administered 6, 12, and 18 hours after initial control is achieved.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo therapy in place of initial and maintenance antivenom therapy. Note that open-label rescue therapy is mandated if the envenomation syndrome becomes severe, or if progression of envenomation signs/symptoms has not spontaneously halted by 6 hours.
Study: NCT00693589

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: folic acid, vitamin B12 and B6 and rosuvastatin
Description: Vitamin supplementation with folic acid 1mg/d, vitamin B12 0.4mg/d and B6 10mg/d po for 6 weeks alone vs. rosuvastatin 10mg/d for 6 weeks alone and thereafter combined treatment for 6 weeks
Study: NCT02700022

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alisertib
Description: Dose escalation of alisertib: level 1 - 20 mg, level 2 - 30 mg, level 3 - 40 mg PO BID on Days 1-5 of six 21-day cycles, combined with R-EPOCH Rituximab, IV infusion on day 1 of each cycle; Etoposide, IV infusion for 96 hours on days 1, 2, 3, and 4 Doxorubicin, IV infusion for 96 hours on days 1, 2, 3, and 4 Vincristine, IV infusion for 96 hours on days 1, 2, 3, and 4 Cyclophosphamide, IV infusion for 15 minutes on day 5 Prednisone, PO daily on days 1, 2, 3, 4, and 5
Study: NCT02787551

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glargine/lixisenatide fixed ratio combination
Description: Pharmaceutical form: solution for injection~Route of administration: subcutaneous

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: liraglutide
Description: Pharmaceutical form: solution for injection~Route of administration: subcutaneous

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: exenatide
Description: Pharmaceutical form: solution for injection~Route of administration: subcutaneous

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: exenatide extended-release
Description: Pharmaceutical form: solution for injection~Route of administration: subcutaneous

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: albiglutide
Description: Pharmaceutical form: solution for injection~Route of administration: subcutaneous

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dulaglutide
Description: Pharmaceutical form: solution for injection~Route of administration: subcutaneous

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Background therapy: Oral Anti-diabetic Drug (Metformin, Pioglitazone, SGLT2 inhibitor)
Description: Pharmaceutical form: tablet Route of administration: oral If previously taken, doses to remain stable through the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Background therapy: Oral Anti-diabetic Drug (Metformin, Pioglitazone, SGLT2 inhibitor)
Description: Pharmaceutical form: tablet Route of administration: oral If previously taken, doses to remain stable through the study.
Study: NCT02276365

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Study: NCT03014492

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Q Collar
Description: Collar designed to mitigate slosh in the brain
Study: NCT03509831

Intervention type: DRUG
Group type: OTHER
Intervention: INT-2150
Description: 1. Period: INT-2150~2. Period: Irsogladine maleate 2 mg+Nizatidine 150 mg

Intervention type: DRUG
Group type: OTHER
Intervention: INT-2150
Description: 1. Period: INT-2150~2. Period: Irsogladine maleate 2 mg+Nizatidine 150 mg

Intervention type: DRUG
Group type: OTHER
Intervention: Irsogladine maleate 2 mg+Nizatidine 150 mg
Description: 1. Period: Irsogladine maleate 2 mg+Nizatidine 150 mg~2. Period: INT-2150

Intervention type: DRUG
Group type: OTHER
Intervention: Irsogladine maleate 2 mg+Nizatidine 150 mg
Description: 1. Period: Irsogladine maleate 2 mg+Nizatidine 150 mg~2. Period: INT-2150
Study: NCT00591266

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilsartan Medoxomil and amlodipine
Description: Azilsartan Medoxomil 40 mg, tablets, orally, once daily and amlodipine 5 mg, tablets, orally, once daily for up to 6 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilsartan Medoxomil and amlodipine
Description: Azilsartan Medoxomil 80 mg, tablets, orally, once daily and amlodipine 5 mg, tablets, orally, once daily for up to 6 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine
Description: Azilsartan medoxomil placebo-matching tablets, orally, once daily and amlodipine 5 mg, tablets, orally, once daily for up to 6 weeks.
Study: NCT00537875

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ginger
Description: Capsule, 1000 mg, BID, 3 days

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule, 1000 mg, BID, 3 days
Study: NCT01135212

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fimasartan 60mg
Description: Fimasartan 60mg for mild to moderate hypertension. Take a tablet(filled in Doubleblind capsule) every morning.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fimasartan 120mg
Description: Fimasartan 120mg for mild to moderate hypertension. Take a tablet(filled in Doubleblind capsule) every morning.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Candesartan cilexetil
Description: Candesartan 8mg for mild to moderate hypertension. Take a tablet(filled in Doubleblind capsule) every morning.
Study: NCT03825744

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hetrombopag Olamine+Standard Therapy
Description: once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo+Standard Therapy
Description: once daily